Search results for "Bordetella"

showing 10 items of 38 documents

Efficacy of Acellular Pertussis Vaccine in Early Childhood After Household Exposure

1996

Objective. —To evaluate the efficacy of a three-dose primary vaccination with a diphtheria-tetanus tricomponent acellular pertussis vaccine against "typical" pertussis, defined as a spasmodic cough of 21 days or longer with confirmation of Bordetella pertussis infection by culture or serology. Design. —Passive monitoring for suspected first household (index) cases of typical pertussis in six areas in Germany comprising 22 505 children vaccinated with study vaccine at 3, 4, and 5 months of age. Blinded, prospective follow-up of household contacts of index cases for incidence and progression of pertussis. Setting. —Six areas in Germany with a high incidence of pertussis. Subjects. —Four hundr…

Bordetella pertussismedicine.medical_specialtyPediatricsbiologybusiness.industryIncidence (epidemiology)General MedicineEnvironmental exposurebiology.organism_classificationmedicine.diseaseVaccine efficacyVaccinationImmunizationEpidemiologyImmunologyMedicinebusinessWhooping coughJAMA: The Journal of the American Medical Association
researchProduct

Immunogenicity of a single dose of reduced-antigen acellular pertussis vaccine in a non-vaccinated adolescent population.

2005

Abstract German adolescents ( n  = 123) without previous pertussis vaccination, no history of pertussis and low IgG-anti-pertussis-toxin (PT) levels received one dose of the Tdap vaccine Boostrix™. Blood samples were taken before, and 5–12 days and 29–49 days after vaccination. IgG- and IgA-anti-PT, IgG- and IgA-anti filamentous hemagglutinin, IgG-anti-pertactin, IgG-anti-tetanus-toxin, and IgG-anti-diphtheria-toxin were measured by ELISA. 88.6% of subjects had an immune response to PT, and all vaccinees had an immune response to at least one pertussis antigen 29–49 days after vaccination. IgA-anti-PT and IgA-anti-FHA responses were found in 43 and 81% of subjects, respectively. This study …

MaleAdolescentWhooping CoughFilamentous haemagglutinin adhesinDiphtheria-Tetanus-acellular Pertussis VaccinesBordetella pertussisImmune systemAntigenImmunitymedicineHumansWhooping coughImmunization ScheduleAntigens BacterialGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryImmunogenicityPublic Health Environmental and Occupational Healthmedicine.diseaseVirologyAntibodies BacterialVaccinationInfectious DiseasesImmunoglobulin GImmunologyMolecular MedicineFemalebusinessAcellular pertussisVaccine
researchProduct

International Bordetella pertussis assay standardization and harmonization meeting report. Centers for Disease Control and Prevention, Atlanta, Georg…

2009

An international meeting on Bordetella pertussis assay standardization and harmonization was held at the Centers for Disease Control and Prevention (CDC), Atlanta, GA, 19-20 July 2007. The goal of the meeting was to harmonize the immunoassays used for pertussis diagnostics and vaccine evaluation, as agreed upon by academic and government researchers, regulatory authorities, vaccine manufacturers, and the World Health Organization (WHO). The primary objectives were (1) to provide epidemiologic, laboratory, and statistical background for support of global harmonization; (2) to overview the current status of global epidemiology, pathogenesis and immunology of pertussis; (3) to develop a consen…

Settore MED/07 - Microbiologia E Microbiologia ClinicaBordetella pertussisStandardizationVaccine evaluationU.S.HarmonizationMedical and Health SciencesArticleBordetella pertussisPertussis vaccinesVirologyHumansMedicineCenters for Disease Control and PreventionWhooping coughLicensureGovernmentMedical educationWhooping coughAgricultural and Veterinary SciencesGeneral VeterinaryGeneral Immunology and MicrobiologybiologyClinical Laboratory Techniquesbusiness.industryPublic Health Environmental and Occupational HealthStandardization of serologic assaysBiological Sciencesbiology.organism_classificationmedicine.diseaseUnited StatesAtlantaInfectious DiseasesImmunologyBordetella pertussis Whooping cough Standardization of serologic assays ELISA Pertussis vaccinesMolecular MedicineELISAbusinessVaccine
researchProduct

Long-term pertussis-specific immune responses to a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine in pre-term…

2002

Abstract Immunoglobulin G (IgG) antibody titres against pertussis antigens, Bordetella pertussis-specific proliferation and cytokine production by peripheral blood mononuclear cells (PBMCs) were evaluated at the age of 5–6 years in 13 children who had been pre-term infants with a gestational age (GA) of ≤31 weeks, 10 who had been pre-term infants with a GA of 32–37 weeks, and 15 who had been term infants with a GA of 38–42 weeks. All of the infants had been immunised with a combined diphtheria, tetanus, tricomponent acellular pertussis and hepatitis B vaccine (DTaP–HBV) at 3, 5, and 11 months of post-natal age. Our results show that the long-term immune responses induced by primary pertussi…

MaleCellular immunityBordetella pertussisTime FactorsHepatitis B vaccineWhooping CoughImmunization SecondaryIn Vitro TechniquesLymphocyte ActivationBordetella pertussisPertussismedicineHumansHepatitis B VaccinesChildDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleWhooping coughHaemophilus VaccinesImmunity CellularPre-term infantsGeneral VeterinaryGeneral Immunology and MicrobiologybiologyTetanusbusiness.industryDiphtheriaDTaP-HBV vaccine; Pertussis; Pre-term infantsAge FactorsInfant NewbornPublic Health Environmental and Occupational Healthmedicine.diseasebiology.organism_classificationAntibodies BacterialVaccinationInfectious DiseasesCase-Control StudiesChild PreschoolImmunoglobulin GImmunologybiology.proteinDTaP-HBV vaccineCytokinesMolecular MedicineFemaleAntibodybusinessInfant PrematureVaccine
researchProduct

Characterisation of a novel airway late phase model in the sensitized guinea pig which uses silica and Bordetella pertussis as adjuvant for sensitiza…

1996

The objective of the present investigation was to validate a novel model of allergic late phase reaction in the airways of conscious guinea pigs by monitoring airway function with CO2-forced respiration. In addition airway inflammation as one possible cause for the development of airway late phase reaction was characterized by a novel technique which consists of bronchoalveolar lavage via the orotracheal route. Guinea pigs were sensitized twice at 2-week intervals with ovalbumin in silica and Bordetella pertussis. Two weeks after the booster sensitization all guinea pigs showed an acute decrease of tidal volume under CO2-forced respiration 5-15 min after antigen challenge. In contrast 42 ou…

MaleBordetella pertussisOvalbuminGuinea PigsAnti-Inflammatory AgentsMethylprednisoloneBordetella pertussisGuinea pigAdjuvants ImmunologicRespiratory HypersensitivityMedicineAnimalsSensitizationPharmacologyCross-Over Studiesmedicine.diagnostic_testbiologybusiness.industryrespiratory systemEosinophilbiology.organism_classificationSilicon Dioxiderespiratory tract diseasesRespiratory Function TestsOvalbuminmedicine.anatomical_structureBronchoalveolar lavageDelayed hypersensitivityImmunologybiology.proteinAirwaybusinessBronchoalveolar Lavage FluidEuropean journal of pharmacology
researchProduct

The seroepidemiology of pertussis in Australia during an epidemic period

2006

Studying the epidemiology of pertussis and impact of differing vaccine schedules is difficult because of differing methods of case ascertainment. The advent of internationally standardized serological diagnosis for recent infection has allowed comparison of age-specific pertussis infection among European countries and was applied in Australia at the time of a major national epidemic. In 1997 and 1998, a nationally representative serum bank using residual sera from diagnostic laboratories was established. Measurement of pertussis toxin (PT) IgG level was conducted by a reference laboratory using an enzyme-linked immunosorbent assay standardized for a number of European countries. A titre of …

medicine.medical_specialtyAdolescentWhooping CoughEpidemiologyVaccination scheduleReference laboratoryPertussis toxinBordetella pertussisSerologySeroepidemiologic StudiesEpidemiologymedicineHumansChildAustralia/epidemiology Diphtheria-Tetanus-Pertussis Vaccine/administration & dosage AdolescentDiphtheria-Tetanus-Pertussis VaccineWhooping coughTransmission (medicine)business.industryAustraliaInfantmedicine.diseaseVaccinationInfectious DiseasesChild PreschoolPopulation SurveillanceImmunologybusinessResearch ArticleDemographyEpidemiology and Infection
researchProduct

IMMUNOGENICITY OF AN ACELLULAR PERTUSSIS VACCINE COMPOSED OF GENETICALLY INACTIVATED PERTUSSIS TOXIN COMBINED WITH FILAMENTOUS HEMAGGLUTININ AND PERT…

1993

We studied the immunogenicity of an acellular pertussis vaccine composed of genetically detoxified pertussis toxin (PT-9K/129G), filamentous haemagglutinin, and a 69-kilodalton protein, pertactin, in 30 children aged 12 to 24 months and in 80 infants aged 2 to 4 months. A significant increase of the neutralizing titer and of the titers against pertussis toxin, filamentous hemagglutinin, and pertactin, as determined by enzyme-linked immunosorbent assay, was achieved after three doses of vaccine in all the children; a significant increase of these antibody titers was obtained in 100%, 96.1%, 93.5%, and 98.7% of the infants, respectively.

Time FactorsFilamentous haemagglutinin adhesinPertussis toxincomplex mixturesBordetella pertussisMicrobiologyNeutralization TestsHumansMedicineVirulence Factors BordetellaAdhesins BacterialImmunization ScheduleWhooping coughPertussis VaccineAntigens Bacterialbusiness.industryImmunogenicitypertussisAntibody titerInfantmedicine.diseaseAntibodies BacterialVirologyVaccinationTiterHemagglutininsPertussis ToxinVaccines InactivatedChild PreschoolImmunoglobulin GPediatrics Perinatology and Child HealthDrug EvaluationPertactinbusinessVaccinepertussis; VaccineBacterial Outer Membrane Proteins
researchProduct

Hemolytic uremic syndrome in an infant following Bordetella pertussis infection.

2006

Reported here is the case of a 6-week-old female infant with a severe Bordetella pertussis infection requiring supportive pressure-positive ventilation in the intensive care unit. After being discharged from the intensive care unit, she developed hemolytic anemia, thrombocytopenia and acute renal failure, which suggested a diagnosis of hemolytic uremic syndrome. The clinical outcome was favorable with no renal consequences. This case suggests there may be a direct cause-effect relationship between B. pertussis infection and hemolytic uremic syndrome.

Microbiology (medical)Hemolytic anemiaPediatricsmedicine.medical_specialtyBordetella pertussisWhooping CoughPertussis toxinBordetella pertussislaw.inventionMedical microbiologylawmedicineHumansbiologybusiness.industryInfantGeneral Medicinebiology.organism_classificationmedicine.diseaseIntensive care unitInfectious DiseasesHemolytic-Uremic SyndromeImmunologyParoxysmal coughFemalebusinessKidney disease
researchProduct

European Sero-Epidemiology Network 2: standardisation of immunoassay results for pertussis requires homogeneity in the antigenic preparations.

2008

A standardisation process, already developed during the earlier European Sero-Epidemiology Network (ESEN) project, was employed with a more robust algorithm to harmonise results of pertussis serological assays performed in 12 European and non-European countries. Initially, results from each country's own assay were compared with those obtained at the reference laboratory by means of an in-house pertussis toxin (PT)-based ELISA: seven countries used in-house or commercial PT-ELISAs; the other countries used assays based on Bordetella pertussis whole cell extracts (WCE) (three countries) or on combined PT-FHA (filamentous haemagglutinin) antigenic preparations (two countries). The WCE assays,…

ESEN (European Sero-Epidemiology Network) Pertussis sero-epidemiology Immunoassay standardisation Pertussis antigenic preparationsBordetella pertussisSettore MED/07 - Microbiologia E Microbiologia ClinicaWhooping CoughPertussis toxinBordetella pertussisSerologyAntigenmedicineSero epidemiologyHumansLow correlationWhooping coughImmunoassayPertussis VaccineAntigens BacterialGeneral VeterinaryGeneral Immunology and Microbiologymedicine.diagnostic_testbiologybusiness.industryPublic Health Environmental and Occupational Healthmedicine.diseasebiology.organism_classificationVirologyAntibodies BacterialEuropeInfectious DiseasesImmunoassayImmunologyCalibrationMolecular MedicinebusinessVaccine
researchProduct

Effect of priming with diphtheria and tetanus toxoids combined with whole-cell pertussis vaccine or with acellular pertussis vaccine on the safety an…

1995

Objective: To evaluate the safety and the immunogenicity of a booster dose of recombinant acellular pertussis vaccine combined with diphtheria and tetanus toxoids (DTaP, Biocine SpA) in 15- to 21-month-old children primed in infancy with either whole-cell diphtheria-tetanus-pertussis (DTwP) vaccine or DTaP vaccine. Design: Open-label second phase of a double-masked, controlled trail, with masked analysis of serum samples. Participants and setting: Three hundred fifty children, 15 to 21 months of age, who had been primed at 2, 4, and 6 months of age with either three doses of DTaP vaccine (n = 173) or DTwP vaccine (n = 177). The children were enrolled in eight vaccination centers in Italy. I…

Time FactorsWhooping CoughImmunization SecondaryEnzyme-Linked Immunosorbent AssayBooster dosecomplex mixturesBordetella pertussisDouble-Blind MethodmedicineHumansVirulence Factors BordetellaDiphtheria-Tetanus-Pertussis VaccineWhooping coughPertussis VaccineVaccines SyntheticTetanusbusiness.industryDiphtheriaToxoidAntibody titerInfantmedicine.diseaseAntibodies BacterialVirologyVACCINE pertussisVaccinationPertussis ToxinPediatrics Perinatology and Child HealthImmunologyPertussis vaccinebusinessFollow-Up Studiesmedicine.drug
researchProduct